HYPOXIA INDUCIBLE FACTOR 2Α (HIF-2Α)

Clinical trials for HYPOXIA INDUCIBLE FACTOR 2Α (HIF-2Α) explained in plain language.

Never miss a new study

Get alerted when new HYPOXIA INDUCIBLE FACTOR 2Α (HIF-2Α) trials appear

Sign up with your email to follow new studies for HYPOXIA INDUCIBLE FACTOR 2Α (HIF-2Α), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

New pill tested for Tough-to-Treat kidney cancer

Disease control Terminated

This study tested a new oral pill called NKT2152 for adults with advanced kidney cancer that had stopped responding to standard treatments. The first part aimed to find a safe and effective dose. The second part planned to see how well the pill could shrink tumors and control the…

Matched conditions: HYPOXIA INDUCIBLE FACTOR 2Α (HIF-2Α)

Phase: PHASE1, PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:33 UTC

HYPOXIA INDUCIBLE FACTOR 2Α (HIF-2Α)

Get alerted when new HYPOXIA INDUCIBLE FACTOR 2Α (HIF-2Α) trials appear

New pill tested for Tough-to-Treat kidney cancer